Inspirna, Inc. is a clinical-stage biopharmaceutical company based in New York, NY, dedicated to developing innovative cancer therapeutics. Utilizing their proprietary RNA-DRIVEr platform, they identify previously unknown drivers of metastasis in common cancers, aiming to convert cancer into a manageable, chronic condition. With a focus on small molecules and biologics, Inspirna's pipeline includes first-in-class oral medications such as ompenaclid RGX-202 for RAS mutant colorectal cancer and abequolixron RGX-104 for non-small cell lung cancer and endometrial cancer.
By providing practical treatment options that prolong survival without compromising patients' quality of life, Inspirna strives to make a significant impact in areas of high unmet need. Their commitment to clinical validation and scientific discovery positions them as a leading player in the field of cancer research and development.
Generated from the website